Potent indole- and quinoline-containing N-methyl-D-aspartate antagonists acting at the strychnine-insensitive glycine binding site

BM Baron, BL Harrison, IA McDonald, BS Meldrum, MG Palfreyman, FG Salituro, BW Siegel, AL Slone, JP Turner and HS White

Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.

The N-methyl-D-aspartate (NMDA)-preferring glutamate receptor subtype possesses, in addition to the recognition site for glutamate, a binding site for glycine. We report here on the pharmacological properties of 3- (4,6-dichloro-2-carboxyindol-3-yl)-propionic acid (MDL 29,951) and 4- carboxymethylamino-5,7-dichloroquinoline-2-carboxylic acid (MDL 100,748), two novel glycine antagonists of NMDA receptor activation in vitro and in vivo. We have measured in parallel the effects of two previously described glycine antagonists, 7-chlorokynurenic acid and 5,7-dichlorokynurenic acid. All were potent inhibitors of [3H]glycine binding. Ki values (microM) were 0.36 (7-chlorokynurenic acid), 0.08 (5,7-dichlorokynurenic acid), 0.07 (MDL 100,748) and 0.14 (MDL 29,951). MDL 100,748 and MDL 29,951 were approximately 2000-fold selective for the glycine binding site relative to the glutamate recognition sites. All four compounds completely inhibited the use-dependent binding of [3H]N-[1-(2-thienyl) cyclohexyl]-piperidine and were noncompetitive, glycine-reversible inhibitors of both NMDA-induced biochemical and electrophysiological responses in brain slice preparations. A competitive interaction with the glycine binding site was also evident in that MDL 29,951 and MDL 100,748 produced parallel rightward shifts in the glycine requirement for demonstration of NMDA-stimulated elevations in cytosolic calcium in cultured neuronal preparations. The glycine antagonists were potent anticonvulsants after their i.c.v. administration to audiogenic seizure-susceptible DBA/2J mice. Because the compounds chosen encompass a variety of chemical structures, the results indicate that glycine is required for NMDA receptor activation and that bioavailable glycine antagonists may form the basis of a novel therapy for epilepsy.

Volume 262, Issue 3, pp. 947-956, 09/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. D. Donevan and R. T. McCabe Conantokin G Is an NR2B-Selective Competitive Antagonist of N-Methyl-D-aspartate Receptors Mol. Pharmacol., September 1, 2000; 58(3): 614 - 623. [Abstract] [Full Text]

				W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]

				E. Viu, A. Zapata, J. L. Capdevila, L. H. Fossom, P. Skolnick, and R. Trullas Glycine Site Antagonists and Partial Agonists Inhibit N-Methyl-D-aspartate Receptor-Mediated [3H]Arachidonic Acid Release in Cerebellar Granule Cells J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 527 - 532. [Abstract] [Full Text]

				M. Takahashi, J. W. Ni, S. Kawasaki-Yatsugi, T. Toya, S.-I. Yatsugi, M. Shimizu-Sasamata, K. Koshiya, J.-I. Shishikura, S. Sakamoto, and T. Yamaguchi YM872, a Novel Selective alpha -Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Antagonist, Reduces Brain Damage after Permanent Focal Cerebral Ischemia in Cats J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 467 - 473. [Abstract] [Full Text]

				C. G. Parsons, W. Danysz, G. Quack, S. Hartmann, B. Lorenz, C. Wollenburg, L. Baran, E. Przegalinski, W. Kostowski, P. Krzascik, et al. Novel Systemically Active Antagonists of the Glycine Site of the N-Methyl-D-aspartate Receptor: Electrophysiological, Biochemical and Behavioral Characterization J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1264 - 1275. [Abstract] [Full Text]